Revvity Inc. (NYSE:RVTY) Stock Has Average Target Price of $124.43 According to Analysts

Shares of Revvity Inc. (NYSE:RVTY) have been given an average recommendation of “Hold” by the eighteen brokerages that are covering the company, MarketBeat reports. Thirteen analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $124.43.

A number of research analysts recently weighed in on the stock. Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Royal Bank Of Canada assumed coverage on Revvity in a research report on Tuesday, September 1st. They set a “sector perform” rating and a $135.00 price objective on the stock. William Blair started coverage on Revvity in a report on Monday, October 5th. They set an “outperform” rating on the stock. Weiss Ratings upgraded shares of Revvity from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Barclays boosted their price target on shares of Revvity from $115.00 to $160.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th.

Revvity Stock Performance

Shares of NYSE:RVTY opened at $156.95 on Tuesday. The company’s 50 day simple moving average is $144.54 and its 200 day simple moving average is $112.15. The stock has a market capitalization of $17.51 billion, a price-to-earnings ratio of 74.74, a price-to-earnings-growth ratio of 2.86 and a beta of 1.06. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. Revvity has a 1 year low of $81.22 and a 1 year high of $169.06.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The company had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. During the same period in the previous year, the business posted $1.18 earnings per share. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts predict that Revvity will post 5.36 EPS for the current fiscal year.

Insider Transactions at Revvity

In related news, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the sale, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. This represents a 9.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tajinder S. Vohra sold 7,330 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. The trade was a 52.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 9,045 shares of company stock worth $1,281,439 over the last ninety days. Insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Revvity

A number of hedge funds have recently modified their holdings of the company. EdgePoint Investment Group Inc. lifted its position in Revvity by 3.1% during the first quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after buying an additional 265,204 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Revvity in the 2nd quarter worth about $961,017,000. Janus Henderson Group PLC grew its position in shares of Revvity by 2.3% in the 1st quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock worth $731,386,000 after buying an additional 186,956 shares during the period. BlackRock Inc. purchased a new stake in shares of Revvity in the 2nd quarter worth about $852,070,000. Finally, State Street Corp grew its position in shares of Revvity by 0.8% in the 2nd quarter. State Street Corp now owns 4,342,739 shares of the company’s stock worth $483,173,000 after buying an additional 32,426 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.